175 #2
12/13/02

In th United States Pat nt and Trademark Office

In re application:	Stable Pharmaceutical Compositions	**Art Unit:**	1751
Application No.:	10/087,951	**Examiner Name:**	
Filed:	03/05/2002		
Inventor Name(s):	Donald L. Barbeau	**Docket No.:**	Barbeau 0302

Commissioner of Patents and Trademarks
Washington, DC 20231

Information Disclosure Statement

Dear Sir:

Please find enclosed an information disclosure statement together with copies of patent and non-patent literature documents for the above-captioned patent application.

Enclosed is a duplicate copy of this letter and a self-addressed pre-stamped return envelope. Please place the Patent Office stamp on this duplicate copy and return to addressee in the pre-stamped envelope.

Respectfully submitted

Donald L. Barbeau
Registration No. 29,766

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington DC 20231 on the date shown below:

Donald L. Barbeau
November 22, 2002

#2

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Complete if Kn wn	
Application Number	10/087,951
Filing Date	03/05/2002
First Named Inventor	Donald L. Barbeau
Art Unit	1751
Examiner Name	
Attorney Docket Number	Barbeau 0302

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number - Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 2,484,029	10/11/1949	Hartman et al.	page 2,col 4; page 3, col 5
		US- 3,840,539	10/08/1974	Ueno et al.	page 1, col 1-2
		US- 4,061,636	12/06/1977	Wise et al.	
		US- 4,757,142	06/12/1988	Pinza et al.	
		US- 4,002,753	01/11/1977	Carpi et al.	
		US- 3,978,057	08/31/1976	Anderson et al.	
		US- 4,478,837	10/23/1984	Schenker	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3] - Number[4] - Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complete if Known	
Application Number	10/087,951
Filing Date	03/05/2002
First Named Inventor	Donald L. Barbeau
Group Art Unit	1751
Examiner Name	
Attorney Docket Number	Barbeau 0302

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		DRUERY, J. AND MARXER, A. Hypotensive Hydrazinopthalines and Related Compounds, Journal of Medicinal and Pharmaceutical Chemistry 1(1): 1-21 (1959) Johnson Reprint Corporation New York	
		SHEPHERD, A. et al. Hydralzine kinetics after single and repeated oral doses,Clinical Pharmacology and Therapeutics 28(6): 804-811(1980)	
		LUDDEN, T.M. et al. Hydralazine kinetics in hypertensive patients after single intravenous administration, Clinical Pharmacology and Therapeutics 28(6): 736-742(1980)	
		HAEGELE K.D. et al. Quantitative Analysis of Hydralzine Pyruvic Acid Hydrazone, The Major Mwetabolite of Hydralazine Journal of Chromatography 187:171-179 (1980)	
		CLEMENTI, W.A. et al. Endogenous Generation of Hydralazine form Labile Hydralazine Hydrazones, Journal of Pharmacology and Experimental Therapeutics 222(1):159-165 (1982)	
		OGISO, T. et al. Pharmacokinetics of Formation and Excretion of Some Metabolites of Hydralazine and Their Hypotensive Effect in Rats, Journal of Pharmacology and Experimental Therapeutics 233(2):485- 490 (1985)	
		IWAKI, M. et al. In Vitro Kinetic Studies of the Reaction of Hydralazine and its Acetone Hydrazone with Pyruvic Acid, Journal of Pharmaceutical Sciences 77(3):280- 283 (1988)	
		McLEAN, A.J. et al. Interaction of Hydralazine and Hydrazone Derivatives with Contractile Mechanisms in Rabbit Aoartic Smooth Muscle, Journal of Pharmacology and Experimental Therapeutics 205(2): 418-425 (1978)	
		HAEGELE, K.D. et al. Identification of Hydrallazine and Hydrallazine Hydrazone Metabolites in Human Body Fluids and In Vitro Comparisons of their Smooth Muscle Activity British, Journal of Clinical Pharmacology 5:489-494 (1978)	
		BARRON, K. et al. Comparative Evaluation of the in vitro Effects of Hydralazine and Hydralazine Acetonide on Arterial Smooth Muscle, British Journal of Pharmacology 621:345-349 (1977)	
		ISRAILI, Z.H. and DAYTON, P.G. Metabolism of Hydralazine Drug, Metabolism Reviews 6(2):283-305 (1977)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

Complete if Known	
Application Number	10/087,951
Filing Date	03/05/2002
First Named Inventor	Donald L. Barbeau
Group Art Unit	1751
Examiner Name	
Attorney Docket Number	Barbeau 0302

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		O'DONNELL, J.P. et al. Kinetic Studies of Hydralazine Reaction with Acetaldehyde, Journal of Pharmaceutical Sciences 68(10): 1256-1258(1979)	
		ZIMMER, H., A Major Metabolit of 1-Hydrazinophthalazine, Arzeim-Forsch 20(10):1586-1587 (1970)	
		TALSETH, T. Pharmacokinetics and Cardiovascular Effects in Rabbits of a Major Hydralazine Metabolite, the Hydralzine Pyruvic-Acid Hydrazone 211(3):509- 513 (1979)	
		McLEAN,A.J. et al. Study of In Vitro Effects of Hydralazine Metabolites -Comparative Evaluation of Products of Hydroxylation, Hydrolysis and Conjguation, Archives Inetrnational Pharmacodynamics 235:19-25 (1978)	
		LaCAGNIN, L.B. et al. Metabolic Activation of Hydralazine by Rat Liver Microsomes, Biochemical Pharmacology 36(16): 2667-2672 (1987)	
		LESSEN, T. A et al. Interactions between Drug Substances and Excipients. 1. Fluorescence and HPLC Studies of Triazophthalazine Derivativces from Hydralazine Hydrochloride and Starch Journal of Pharmaceutical Sciences 85(3): 326-329 (1996)	
		SCHNECK,D.W. et al. Plasma levels of free and acid-labile hydralazine: Effects of multiple dosing and of procainamide Clinical Pharmacology and Therapeutics 24(6): 714-719 (1978)	
		TALSETH T. et al. Hypotensive Effect of the Hydralazine-Acetone Hydrazone in Conscious Rabbits: Evidence for its Back-Conversion to Hydralazine In Vivo , Journal of Cardiovascular Pharmacology 4: 370-374 (1982)	
		McLEAN, A.J. et al. Comparative Evaluation of the Hypotensive Activity of Two Major Metabolites of Hydralazine (1-Hydrazinophthalazine) European Journal of Drug Metabolism and Pharmacokinetics 1: 17-20 (1977)	
		JUCHAU, M.R. AND HORITA, A. Metabolism of Hydralazine Derivatives of Pharmacological Interest, Drug Metabolism Reviews 1(1): 71-100 (1972)	
		HAEGELE, K.D. et al. Determination of Hydralazine and its Metabolites by Gas Chromatography-Mass Spectrometry Journal of Chromatography 126:517-534 (1976)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 4

Complete if Known	
Application Number	10/087,951
Filing Date	03/05/2002
First Named Inventor	Donald L. Barbeau
Group Art Unit	1751
Examiner Name	
Attorney Docket Number	Barbeau 0302

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		LUDDEN et al,.High-Pressure Liquid Chromatography Assay for Hydralazine in Human Plasma, Journal of Pharmaceutical Sciences 63(11) 1423-1425(1979)	
		O'DONNELL, J.P., et al. ,.High-Pressure Liquid Chromatography Studies of Reaction of Hydralazine in with Biogenic Aldehydes and Ketones, Journal of Pharmaceutical Sciences 68(12) 1524-1526(1979)	
		REECE, P.A., et al. Selective High-Performance Liquid Chromatographic Assays for Hydralazine and it Metabolites in Plasma of Man, Journal of Chromatography 181:427-440 (1980)	
		LACAGNIN, L.B. Separation and Quantitation of Hydralazine Metabolites by High-Performance Liquid Chromatogaphy, Journal of Chromatography 377:319-327 (1986)	
		IWAKA, M. ET AL. Pharmacokinetics and Biotranformation of Hydralazine Acetone Hydrazone, a Metabolite of Hydralazine, in the Rat , Journal of Pharmaceutical Sciences 78(10):867-873(1989)	
		KANAZAWA, H. et al. New Degradation Products in an Aqueous Solution of Hydralazine Hydrochloride with Cimetidine, Chem. Pharm. Bull. 34(4(:1840-1842 (1986)	
		SCHULER, W. AND WYSS. E., Zur Frage Der Spezifitat Der Wirkung Blutdrucksenkender Und Rerpinpin-Antagonistich . . .Arch. Int. Pharmacodyn. CXXVIII(3-4):431- 468 (1960)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.